2026

1. Correction: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801 (Clinical and Translational Oncology, (2025), 28, 6, (2377-2385), 10.1007/s12094-025-04164-w)

   Clinical and Translational Oncology

2. Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study

   Cancer, Vol. 132, Núm. 14

3. Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801)

   Clinical and Translational Oncology, Vol. 28, Núm. 1, pp. 320-329

4. Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801

   Clinical and Translational Oncology, Vol. 28, Núm. 6, pp. 2377-2385